Nicolas Mottet: How to organize PSA screening
•
0 likes•735 views
This document discusses guidelines for prostate cancer screening in 2019. It recommends: 1) Unchanged screening guidelines from 2019 - screening at-risk populations and considering early PSA screening from ages 40-45. 2) Risk calculators and MRI can help determine who needs biopsies and reduce unnecessary biopsies by around 30-40%. 3) There is no definitive age limit for stopping screening, but comorbidities should be considered using tools like the Charlson comorbidity index. 4) Early diagnosis through screening remains important to find aggressive early lesions, but screening must be individualized and include counseling to avoid overtreatment.
Report
Share
Report
Share
Download to read offline
Recommended
Peter Albers: Risk adapted screening
This document discusses prostate cancer (PCA) screening and proposes a risk-adapted early screening program called PROBASE. It notes that PCA mortality ranks 2nd in Germany and worldwide but there is no early detection program for prostate cancer like there is for colorectal cancer. It then compares mortality reduction methods for various cancers and screening programs. The document proposes a risk-adapted PCA screening trial that would assign men to screening intervals based on their baseline PSA at age 45 and risk factors. This would potentially prevent overdiagnosis while still identifying early cancers.
Hein Van Poppel: time to reconsider PSA screening?
The document discusses reconsidering prostate-specific antigen (PSA) screening for prostate cancer. It notes that while PSA screening can detect cancer early, its implementation was discouraged due to overdiagnosis and overtreatment. However, new techniques and active surveillance may help avoid these issues. The document argues that screening could save lives and money by finding cancer earlier when treatment has fewer side effects and costs less. It calls for reconsidering structured, population-based PSA screening and developing partnerships to prevent and treat prostate cancer.
Monique Roobol: Risk Stratification
1) PSA screening, when combined with risk stratification and MRI, can help identify those men who will benefit from early prostate cancer testing while avoiding overdiagnosis and unnecessary biopsies in others.
2) Using PSA levels and age to stratify risk, about 30-50% of men could avoid further testing with PSA <1 ng/ml. Targeted biopsies guided by MRI can reduce unnecessary biopsies by up to 68%.
3) An approach using initial PSA testing followed by reflex testing or MRI based on PSA levels and age could lower the number needed to screen to detect one prostate cancer death to around 1,700.
Monique Roobol: PSA History
This document discusses the history of prostate cancer screening and the role of PSA testing. It notes that in the pre-screening era, 30-35% of men were diagnosed with bone metastases and 45-50% with nodal disease. PSA testing led to more early-stage diagnoses and declining metastatic disease and mortality rates. However, PSA testing rates have declined in recent years in some countries, which could lead to more advanced cases being detected if screening is not continued in a targeted way to avoid overtesting. The optimal path forward is debated.
Per-Anders Abrahamsson: Prostate cancer screening in sweden
Prostate cancer screening in Sweden is organized to maximize benefits and minimize harms. Data shows that 10,440 Swedish men were diagnosed with prostate cancer in 2015, with 2,356 dying from it. Longer follow up of screening trials show that regular PSA-based screening can significantly reduce prostate cancer mortality by up to 44% with a favorable number needed to screen and diagnose. Screening should start by age 50 and be risk-stratified based on age, PSA levels and health to determine frequency. New tests may improve detection of high-grade cancers and reduce unnecessary biopsies. Sweden also leads in active surveillance of low-risk prostate cancer cases.
Andre Deschamps: Europa Uomo - patient's perspective
André Deschamps argues that a new strategy is needed for prostate cancer screening and treatment in Europe. Only 48% of European men are aware of prostate cancer risks and screening options, and only 50% of healthcare professionals actively promote PSA testing. Additionally, only 19% of diagnosed men receive treatment within a month, and only 64% have access to active surveillance when appropriate. Deschamps calls for increased awareness of prostate cancer, improved access to cancer centers, and PSA-led screening programs.
Tit Albreht: Reflections on early detection and screening
This document discusses strategies for cancer screening and early detection, particularly for men. It identifies key topics such as cancer prevention, public health genomics, cancer registries, challenges in cancer care, and innovative therapies. It emphasizes the importance of encouraging screening and early detection for men through positive messages and identifying socially vulnerable groups. Challenges include developing approaches to increase preventative activities for men and identifying gaps through screening and early detection. Both screening and early detection are important but screening requires evidence of population-level benefits and not all cancers can be screened for. Early detection may encourage hesitant individuals and acknowledge the cancer issue. Current challenges include a lack of guidelines leaving room for variation and not adequately risk stratifying or involving primary care.
Prostate Cancer Treatment - Active Surveillance
Prostate cancer is commonly diagnosed in men over 50. If detected early, physicians may recommend active surveillance which involves close monitoring of cancer progression through regular PSA blood tests, ultrasounds, and rectal exams. This allows patients to delay more aggressive treatments like surgery and radiation therapy unless the cancer becomes more advanced or aggressive over time.
Recommended
Peter Albers: Risk adapted screening
This document discusses prostate cancer (PCA) screening and proposes a risk-adapted early screening program called PROBASE. It notes that PCA mortality ranks 2nd in Germany and worldwide but there is no early detection program for prostate cancer like there is for colorectal cancer. It then compares mortality reduction methods for various cancers and screening programs. The document proposes a risk-adapted PCA screening trial that would assign men to screening intervals based on their baseline PSA at age 45 and risk factors. This would potentially prevent overdiagnosis while still identifying early cancers.
Hein Van Poppel: time to reconsider PSA screening?
The document discusses reconsidering prostate-specific antigen (PSA) screening for prostate cancer. It notes that while PSA screening can detect cancer early, its implementation was discouraged due to overdiagnosis and overtreatment. However, new techniques and active surveillance may help avoid these issues. The document argues that screening could save lives and money by finding cancer earlier when treatment has fewer side effects and costs less. It calls for reconsidering structured, population-based PSA screening and developing partnerships to prevent and treat prostate cancer.
Monique Roobol: Risk Stratification
1) PSA screening, when combined with risk stratification and MRI, can help identify those men who will benefit from early prostate cancer testing while avoiding overdiagnosis and unnecessary biopsies in others.
2) Using PSA levels and age to stratify risk, about 30-50% of men could avoid further testing with PSA <1 ng/ml. Targeted biopsies guided by MRI can reduce unnecessary biopsies by up to 68%.
3) An approach using initial PSA testing followed by reflex testing or MRI based on PSA levels and age could lower the number needed to screen to detect one prostate cancer death to around 1,700.
Monique Roobol: PSA History
This document discusses the history of prostate cancer screening and the role of PSA testing. It notes that in the pre-screening era, 30-35% of men were diagnosed with bone metastases and 45-50% with nodal disease. PSA testing led to more early-stage diagnoses and declining metastatic disease and mortality rates. However, PSA testing rates have declined in recent years in some countries, which could lead to more advanced cases being detected if screening is not continued in a targeted way to avoid overtesting. The optimal path forward is debated.
Per-Anders Abrahamsson: Prostate cancer screening in sweden
Prostate cancer screening in Sweden is organized to maximize benefits and minimize harms. Data shows that 10,440 Swedish men were diagnosed with prostate cancer in 2015, with 2,356 dying from it. Longer follow up of screening trials show that regular PSA-based screening can significantly reduce prostate cancer mortality by up to 44% with a favorable number needed to screen and diagnose. Screening should start by age 50 and be risk-stratified based on age, PSA levels and health to determine frequency. New tests may improve detection of high-grade cancers and reduce unnecessary biopsies. Sweden also leads in active surveillance of low-risk prostate cancer cases.
Andre Deschamps: Europa Uomo - patient's perspective
André Deschamps argues that a new strategy is needed for prostate cancer screening and treatment in Europe. Only 48% of European men are aware of prostate cancer risks and screening options, and only 50% of healthcare professionals actively promote PSA testing. Additionally, only 19% of diagnosed men receive treatment within a month, and only 64% have access to active surveillance when appropriate. Deschamps calls for increased awareness of prostate cancer, improved access to cancer centers, and PSA-led screening programs.
Tit Albreht: Reflections on early detection and screening
This document discusses strategies for cancer screening and early detection, particularly for men. It identifies key topics such as cancer prevention, public health genomics, cancer registries, challenges in cancer care, and innovative therapies. It emphasizes the importance of encouraging screening and early detection for men through positive messages and identifying socially vulnerable groups. Challenges include developing approaches to increase preventative activities for men and identifying gaps through screening and early detection. Both screening and early detection are important but screening requires evidence of population-level benefits and not all cancers can be screened for. Early detection may encourage hesitant individuals and acknowledge the cancer issue. Current challenges include a lack of guidelines leaving room for variation and not adequately risk stratifying or involving primary care.
Prostate Cancer Treatment - Active Surveillance
Prostate cancer is commonly diagnosed in men over 50. If detected early, physicians may recommend active surveillance which involves close monitoring of cancer progression through regular PSA blood tests, ultrasounds, and rectal exams. This allows patients to delay more aggressive treatments like surgery and radiation therapy unless the cancer becomes more advanced or aggressive over time.
EPAD 2017 - Paul Enders
PCa screening from a patient perspective
Paul Enders, Europa Uomo and member EAU PCa Guidelines Panel
Active Surveillance for Prostate Cancer
This document discusses active surveillance for prostate cancer. It defines active surveillance as monitoring low-risk prostate cancer through regular testing and biopsies, and only providing invasive treatment if signs of cancer growth appear. Active surveillance is indicated for younger men with low-risk cancer defined by grade, tumor extent and other clinical criteria. Studies show active surveillance can effectively manage low-risk cancer with low rates of cancer-specific mortality and metastasis over long-term follow-up while avoiding overtreatment. Improving patient selection, monitoring methods, and confidence in active surveillance can help optimize its use in managing prostate cancer in Europe.
EPAD 2017 - Nicolas Mottet
1) Prostate cancer is not an indolent disease and is the 2nd or 3rd leading cause of cancer death despite late clinical symptoms, highlighting controversies in screening.
2) The EAU guidelines are evidence-based and updated yearly, involving multiple medical specialties including urologists, oncologists, and a patient representative, and are endorsed by 50 national urological associations across Europe.
3) Screening reduces prostate cancer mortality according to multiple large studies, but there remains a question about diagnosing "insignificant prostate cancer" and whether diagnosis must mean treatment.
EPAD 2017 - Bertrand Tombal
Prevention of Prostate Cancer
Bertrand Tombal, President of the European Organisation for Research and Treatment of Cancer (EORTC)
EPAD 2017 - James N'Dow
This document discusses how big data can be used to address major challenges in prostate cancer research and clinical practice. It proposes a model to create a standardized, collaborative data platform that integrates large clinical datasets from multiple European and non-European sources. This would allow for novel analytics and computational approaches to gain new insights into prostate cancer outcomes and improve standardized care pathways. Key elements for success include involvement of experts in prostate cancer and big data as well as all stakeholders, including patients. Education is needed to encourage data sharing while protecting privacy.
EPAD 2017 - Jochen Walz
Recent developments in early diagnosis for PCa
Jochen Walz , Chair EAU Section on Urological Imaging (ESUI)
Prostate cancer detection, UroLifts, Haematuria
This document discusses innovations in prostate disease management, including focal therapy options for prostate cancer and the UroLift procedure for treating benign prostatic hyperplasia (BPH). It summarizes guidelines for investigating hematuria and evaluating prostate cancer risk. It also compares treatment options for localized prostate cancer and BPH, noting UroLift offers symptom relief while preserving sexual function unlike other BPH treatments. Clinical data shows UroLift improves urinary symptoms and quality of life compared to TURP, with faster recovery and no effect on ejaculation.
What’s new in prostate cancer part 1, 2021
1) Prostate cancer screening is controversial because while screening can reduce prostate cancer mortality, it also leads to overdiagnosis and overtreatment of indolent cancers.
2) The PSA test is an imperfect screening test that does not perfectly predict who needs a biopsy or aggressive treatment. Newer tests may help better identify high-risk cancers.
3) Most prostate cancers grow slowly and will not cause harm. Screening identifies many localized or regional cancers with nearly 100% 5-year survival rates.
EPAD 2017 - Vitaly Smelov
Prevention and early detection of Prostate Cancer: a global view Vitaly Smelov, International Agency for Research on Cancer (IARC), World Health Organisation (WHO)
Chris Chapple: Welcome
Prostate cancer is the most commonly diagnosed cancer among men in Europe, with over 417,000 new cases each year. More than 2 million European men are currently living with prostate cancer, and over 92,000 die from the disease annually. The total yearly costs of prostate cancer in Europe exceed 9 billion euros. As populations age and more men survive other diseases, the burden of prostate cancer is expected to increase dramatically in the coming years through higher incidence, prevalence, and costs. Improved screening and treatment can help reduce mortality rates and improve quality of life, but a coordinated effort at the European Union level is needed to prioritize prostate cancer care.
Screening and prostate cancer
Screening for prostate cancer remains controversial due to the high risk of overdiagnosis and overtreatment. While screening can find early-stage cancers, most prostate cancers grow slowly and will not cause harm. Screening often leads to unnecessary biopsies, treatments and side effects like impotence and incontinence without clear benefits. Younger, low-risk men are unlikely to benefit from PSA screening, while older men or those at higher risk may benefit if screening finds aggressive cancers early. Active surveillance is often preferred over immediate treatment for low-risk prostate cancers found by screening. Overall, more research is still needed to determine which men would benefit most from prostate cancer screening.
Multidisciplinarity and the Prostate Cancer Unit
This document discusses the benefits and structure of a Prostate Cancer Unit (PCU). Key points include:
- A PCU is a multidisciplinary team approach that can improve outcomes for prostate cancer patients through coordinated care.
- The core team of a PCU includes urologists, radiation oncologists, medical oncologists, pathologists, nurses, and data managers who work together.
- A successful PCU sees over 100 new prostate cancer cases per year, follows evidence-based guidelines, and facilitates access to rehabilitation and palliative care programs.
Prostate Cancer Testing and Screening
An overview of issues associated with prostate cancer testing and screening. Part of a larger online course.
EPAD 2017 Ian Banks
Addressing inequalities in access to care for PCa in Europe
Ian Banks, President European Men’s Health Forum (EMHF)
Prostate Cancer And Screening
Screening for Prostate cancer has had many different opinions and much research has been conducted in the last 20 years. In this presentation we will discuss the current guidelines for proper screening and gain more insight into men’s health.
Prostate Cancer Resources
September is National Prostate Cancer Awareness Month. Here are some helpful resources in honor of Prostate Cancer Awareness Month.
PSA test accuracy
1) The accuracy of the PSA test for detecting prostate cancer depends on the age of the patient and the prevalence of prostate cancer, which increases significantly with age.
2) For patients under 70 years old, the PSA test has very low accuracy, ranging from near 0% to 22% accuracy, which could lead to many unnecessary invasive biopsies.
3) The U.S. Preventive Services Task Force recommends against PSA-based prostate cancer screening for men 75 and older, and makes no recommendation for men under 75 due to inadequate evidence that screening improves health outcomes.
MON 2011 - Slide 1 - K. Fizazi - Spotlight session - New developments in the ...
MON 2011 - Slide 1 - K. Fizazi - Spotlight session - New developments in the ...European School of Oncology
Localized prostate cancer is the most common cancer in men in Western countries. For patients with high risk localized prostate cancer, the current recommended treatment is androgen deprivation therapy combined with radiotherapy. Several large randomized controlled trials have shown this combination prolongs progression-free and overall survival compared to androgen deprivation alone. Additional treatment options for high risk localized prostate cancer currently being investigated include radical prostatectomy and chemotherapy with docetaxel. Erectile dysfunction is a common side effect of treatment that can be addressed with oral phosphodiesterase inhibitors or intracavernosal injections.Prostate cancer Organ Confined by Dr. Ali Mujtaba
organ-confined prostate cancer by Dr. Ali Mujtaba (Resident Urology) Sindh Institute of Urology and Transplantation (SIUT)
What’s new in prostate cancer part 2, 2021
How to make treatment decisions about prostate cancer, When is watchful waiting appropriate and how to chose between radiation or surgery.
Cancer screening for seniors
This document discusses cancer screening for seniors and whether it makes sense. It notes that reasons not to screen everyone include costs, potential harms from false positives or procedures, and factors related to life expectancy and health status. It provides examples of famous people who died of pancreatic cancer and notes that screening for pancreatic cancer is not recommended. It asks questions about the most common cancers, typical cancer ages, beneficial screening tests, and best screening advice. It discusses stopping screening at age 75 but continuing for those expected to live 10 more years. It provides resources on cancer screening guidelines.
pca screening.pdf
Prostate cancer screening and early detection is an ongoing area of research and debate. While screening can detect prostate cancer earlier when it may be more treatable, it also leads to overdiagnosis and overtreatment. Several large clinical trials have had conflicting results on the benefits of prostate cancer screening. Guidelines from organizations also vary in their recommendations for screening. New biomarkers and imaging techniques are being studied to improve screening specificity and reduce unnecessary biopsies and treatment. Overall, the effectiveness of prostate cancer screening remains uncertain, and any decision to be screened requires informed discussion of risks and benefits.
More Related Content
What's hot
EPAD 2017 - Paul Enders
PCa screening from a patient perspective
Paul Enders, Europa Uomo and member EAU PCa Guidelines Panel
Active Surveillance for Prostate Cancer
This document discusses active surveillance for prostate cancer. It defines active surveillance as monitoring low-risk prostate cancer through regular testing and biopsies, and only providing invasive treatment if signs of cancer growth appear. Active surveillance is indicated for younger men with low-risk cancer defined by grade, tumor extent and other clinical criteria. Studies show active surveillance can effectively manage low-risk cancer with low rates of cancer-specific mortality and metastasis over long-term follow-up while avoiding overtreatment. Improving patient selection, monitoring methods, and confidence in active surveillance can help optimize its use in managing prostate cancer in Europe.
EPAD 2017 - Nicolas Mottet
1) Prostate cancer is not an indolent disease and is the 2nd or 3rd leading cause of cancer death despite late clinical symptoms, highlighting controversies in screening.
2) The EAU guidelines are evidence-based and updated yearly, involving multiple medical specialties including urologists, oncologists, and a patient representative, and are endorsed by 50 national urological associations across Europe.
3) Screening reduces prostate cancer mortality according to multiple large studies, but there remains a question about diagnosing "insignificant prostate cancer" and whether diagnosis must mean treatment.
EPAD 2017 - Bertrand Tombal
Prevention of Prostate Cancer
Bertrand Tombal, President of the European Organisation for Research and Treatment of Cancer (EORTC)
EPAD 2017 - James N'Dow
This document discusses how big data can be used to address major challenges in prostate cancer research and clinical practice. It proposes a model to create a standardized, collaborative data platform that integrates large clinical datasets from multiple European and non-European sources. This would allow for novel analytics and computational approaches to gain new insights into prostate cancer outcomes and improve standardized care pathways. Key elements for success include involvement of experts in prostate cancer and big data as well as all stakeholders, including patients. Education is needed to encourage data sharing while protecting privacy.
EPAD 2017 - Jochen Walz
Recent developments in early diagnosis for PCa
Jochen Walz , Chair EAU Section on Urological Imaging (ESUI)
Prostate cancer detection, UroLifts, Haematuria
This document discusses innovations in prostate disease management, including focal therapy options for prostate cancer and the UroLift procedure for treating benign prostatic hyperplasia (BPH). It summarizes guidelines for investigating hematuria and evaluating prostate cancer risk. It also compares treatment options for localized prostate cancer and BPH, noting UroLift offers symptom relief while preserving sexual function unlike other BPH treatments. Clinical data shows UroLift improves urinary symptoms and quality of life compared to TURP, with faster recovery and no effect on ejaculation.
What’s new in prostate cancer part 1, 2021
1) Prostate cancer screening is controversial because while screening can reduce prostate cancer mortality, it also leads to overdiagnosis and overtreatment of indolent cancers.
2) The PSA test is an imperfect screening test that does not perfectly predict who needs a biopsy or aggressive treatment. Newer tests may help better identify high-risk cancers.
3) Most prostate cancers grow slowly and will not cause harm. Screening identifies many localized or regional cancers with nearly 100% 5-year survival rates.
EPAD 2017 - Vitaly Smelov
Prevention and early detection of Prostate Cancer: a global view Vitaly Smelov, International Agency for Research on Cancer (IARC), World Health Organisation (WHO)
Chris Chapple: Welcome
Prostate cancer is the most commonly diagnosed cancer among men in Europe, with over 417,000 new cases each year. More than 2 million European men are currently living with prostate cancer, and over 92,000 die from the disease annually. The total yearly costs of prostate cancer in Europe exceed 9 billion euros. As populations age and more men survive other diseases, the burden of prostate cancer is expected to increase dramatically in the coming years through higher incidence, prevalence, and costs. Improved screening and treatment can help reduce mortality rates and improve quality of life, but a coordinated effort at the European Union level is needed to prioritize prostate cancer care.
Screening and prostate cancer
Screening for prostate cancer remains controversial due to the high risk of overdiagnosis and overtreatment. While screening can find early-stage cancers, most prostate cancers grow slowly and will not cause harm. Screening often leads to unnecessary biopsies, treatments and side effects like impotence and incontinence without clear benefits. Younger, low-risk men are unlikely to benefit from PSA screening, while older men or those at higher risk may benefit if screening finds aggressive cancers early. Active surveillance is often preferred over immediate treatment for low-risk prostate cancers found by screening. Overall, more research is still needed to determine which men would benefit most from prostate cancer screening.
Multidisciplinarity and the Prostate Cancer Unit
This document discusses the benefits and structure of a Prostate Cancer Unit (PCU). Key points include:
- A PCU is a multidisciplinary team approach that can improve outcomes for prostate cancer patients through coordinated care.
- The core team of a PCU includes urologists, radiation oncologists, medical oncologists, pathologists, nurses, and data managers who work together.
- A successful PCU sees over 100 new prostate cancer cases per year, follows evidence-based guidelines, and facilitates access to rehabilitation and palliative care programs.
Prostate Cancer Testing and Screening
An overview of issues associated with prostate cancer testing and screening. Part of a larger online course.
EPAD 2017 Ian Banks
Addressing inequalities in access to care for PCa in Europe
Ian Banks, President European Men’s Health Forum (EMHF)
Prostate Cancer And Screening
Screening for Prostate cancer has had many different opinions and much research has been conducted in the last 20 years. In this presentation we will discuss the current guidelines for proper screening and gain more insight into men’s health.
Prostate Cancer Resources
September is National Prostate Cancer Awareness Month. Here are some helpful resources in honor of Prostate Cancer Awareness Month.
PSA test accuracy
1) The accuracy of the PSA test for detecting prostate cancer depends on the age of the patient and the prevalence of prostate cancer, which increases significantly with age.
2) For patients under 70 years old, the PSA test has very low accuracy, ranging from near 0% to 22% accuracy, which could lead to many unnecessary invasive biopsies.
3) The U.S. Preventive Services Task Force recommends against PSA-based prostate cancer screening for men 75 and older, and makes no recommendation for men under 75 due to inadequate evidence that screening improves health outcomes.
MON 2011 - Slide 1 - K. Fizazi - Spotlight session - New developments in the ...
MON 2011 - Slide 1 - K. Fizazi - Spotlight session - New developments in the ...European School of Oncology
Localized prostate cancer is the most common cancer in men in Western countries. For patients with high risk localized prostate cancer, the current recommended treatment is androgen deprivation therapy combined with radiotherapy. Several large randomized controlled trials have shown this combination prolongs progression-free and overall survival compared to androgen deprivation alone. Additional treatment options for high risk localized prostate cancer currently being investigated include radical prostatectomy and chemotherapy with docetaxel. Erectile dysfunction is a common side effect of treatment that can be addressed with oral phosphodiesterase inhibitors or intracavernosal injections.Prostate cancer Organ Confined by Dr. Ali Mujtaba
organ-confined prostate cancer by Dr. Ali Mujtaba (Resident Urology) Sindh Institute of Urology and Transplantation (SIUT)
What’s new in prostate cancer part 2, 2021
How to make treatment decisions about prostate cancer, When is watchful waiting appropriate and how to chose between radiation or surgery.
What's hot (20)
MON 2011 - Slide 1 - K. Fizazi - Spotlight session - New developments in the ...
MON 2011 - Slide 1 - K. Fizazi - Spotlight session - New developments in the ...
Similar to Nicolas Mottet: How to organize PSA screening
Cancer screening for seniors
This document discusses cancer screening for seniors and whether it makes sense. It notes that reasons not to screen everyone include costs, potential harms from false positives or procedures, and factors related to life expectancy and health status. It provides examples of famous people who died of pancreatic cancer and notes that screening for pancreatic cancer is not recommended. It asks questions about the most common cancers, typical cancer ages, beneficial screening tests, and best screening advice. It discusses stopping screening at age 75 but continuing for those expected to live 10 more years. It provides resources on cancer screening guidelines.
pca screening.pdf
Prostate cancer screening and early detection is an ongoing area of research and debate. While screening can detect prostate cancer earlier when it may be more treatable, it also leads to overdiagnosis and overtreatment. Several large clinical trials have had conflicting results on the benefits of prostate cancer screening. Guidelines from organizations also vary in their recommendations for screening. New biomarkers and imaging techniques are being studied to improve screening specificity and reduce unnecessary biopsies and treatment. Overall, the effectiveness of prostate cancer screening remains uncertain, and any decision to be screened requires informed discussion of risks and benefits.
Evolving recommendations in prostate cancer screening
Prostate cancer screening recommendations have evolved as more evidence has emerged. Early approaches recommended annual PSA screening for all men over 50, but two large trials had conflicting results. One found no mortality benefit, while the other found a 21% reduction in men aged 55-69. However, significant overdiagnosis and harms were recognized, including false positives in 75% of biopsied men. Current guidelines recommend shared decision making for screening in men 55-69 and against screening for other age groups. Improved tests are still needed to better distinguish indolent from aggressive cancers.
Reducing the burden of prostate cancer
This document outlines a 3-point plan to reduce the burden of prostate cancer: 1) Integrate available information to calculate individual risk; 2) Use modern diagnostic imaging and biopsy techniques; 3) Treatment for early prostate cancer in the right patient reduces mortality. It discusses using risk calculators and family history to determine risk, multiparametric MRI and PCA3 testing to accurately diagnose cancer, and robotic surgery for high-grade tumors to improve cancer control, continence and potency outcomes. The goal is to precisely diagnose and treat those who will benefit from intervention to reduce death rates.
Prostate cancer modernising the diagnostic pathway 2013-06-11 by Marc Laniado
This document discusses modernizing the diagnostic pathway for prostate cancer. It notes that prostate cancer cases are projected to increase by 70% by 2030 without changes. The current tissue diagnosis pathway is deemed unfit for today. Multiparametric MRI is highlighted as the best current test for localizing and characterizing prostate cancer. Targeted biopsies guided by MRI are presented as a more accurate alternative to unguided biopsies. An optimal pathway is proposed utilizing risk calculation, multiparametric MRI, and targeted biopsies to safely diagnose significant cancers while avoiding overdiagnosis. Guidelines for early detection in different age groups are also reviewed.
BALKAN MCO 2011 - A. Anttila - The European Commission programme for cervical...
BALKAN MCO 2011 - A. Anttila - The European Commission programme for cervical...European School of Oncology
1) Cervical cancer screening programs in the EU have reduced cervical cancer rates but coverage and adherence remain uneven across countries.
2) Barriers to effective screening include a lack of organized, population-based programs in some countries and low attendance rates due to cultural and access factors.
3) New screening technologies like HPV testing may further reduce cancer rates if implemented carefully through organized screening programs.Overdiagnosis in cancer
Cancer screening may discover many dormant, regressing, or slowly progressing tumors that would not have affected the screened individuals. Such findings with there therapies are obviously harmful. This lecture is highly based on the book "over diagnosed" by H. Gilbert Welch and was presented in 2013 to KFSH-Dammam physicians
CESONCO200104-Tamizaje contra el cáncer
The document discusses cancer screening and provides information about different screening tests. It notes that screening aims to detect cancers early through tests conducted on asymptomatic people. Screening tests discussed include mammography for breast cancer, PSA tests for prostate cancer, colonoscopies for colorectal cancer, CT scans for lung cancer, and Pap smears for cervical cancer. However, some screening tests have not been proven to actually decrease cancer mortality and can lead to overdiagnosis and overtreatment. There is ongoing debate around the risks and benefits of cancer screening tests.
Screening for prostate cancer 2018
Understanding the controversy about PSA screening for prostate cancer and how new staging and genomics may impact this disease
Prostate cancer (screening)
1. The document discusses the debate around prostate cancer screening in elderly men over age 65, with arguments on both sides.
2. Screening may detect cancers early that would not have progressed or caused harm in a man's lifetime given his life expectancy. However, screening also risks overdiagnosis and overtreatment of biologically unimportant cancers.
3. Guidelines in the US do not recommend routine screening for low-risk, elderly patients due to the scientific uncertainties around the balance of benefits and harms. Patient-clinician discussion is important to make informed, individual decisions.
Point counterpoint in PCa screening
1. The document discusses whether prostate cancer screening should be recommended for elderly men over age 65 given the high prevalence of prostate cancer but also the slow growing nature in many cases and short life expectancy.
2. While screening can detect cancer early, it also risks overdiagnosing biologically unimportant cancers and subjects men to potential harms of treatment without clear benefits due to their age.
3. Guidelines in the US have differing recommendations regarding screening older men, reflecting the ongoing debate around the balance of risks and benefits in this population.
Update in cancer screening venezuela
This document provides updates to guidelines for several types of cancer screening, including breast, colorectal, cervical, prostate, lung, and ovarian cancer. For each cancer, it discusses what screening tests are recommended, for which populations and age groups, and how frequently screening should occur. It also notes some controversial issues and new recommendations from groups like the US Preventive Services Task Force.
Cervical Cancer Screening - HPV - www.jinekolojivegebelik.com
The document discusses guidelines for cervical cancer screening, including incorporating HPV testing. It finds that HPV testing for women over 30 with ASCUS can reduce unnecessary colposcopies by identifying HPV-negative patients with very low risk. However, HPV testing also poses problems like increased anxiety and many HPV-positive women referred for colposcopy having normal results. Overall, HPV testing may help triage some abnormal pap results but also adds new issues to consider.
Update on screening for breast and lung cancer
Presentation on updated information on breast and lung cancer screening from Penn Medicine's Dr. Antje Greenfield.
Super early cancer screening for the ultra rich Asian
This presentation talks about the nonconventional ways to look for cancer. It discusses next generation sequencing for multilane panels for cancer predisposition syndromes, whole genome sequencing, circulating tumor cells, circulating tumor DNA, and CancerSEEK. It also discusses the traditional cancer screening guidelines by the American Cancer Society and the USPSTF.
Management and prevention of cervical cancer.pptx
The document provides an overview of cervical cancer including:
- It is the 4th most common cancer in women worldwide and is caused by HPV infection.
- Risk factors include early sexual activity, multiple partners, smoking, and immunosuppression.
- Prevention involves HPV vaccines and screening like Pap tests or HPV tests. Abnormal results may require further tests or treatment.
- Stages of cervical cancer are described along with management approaches like surgery, radiation, or chemotherapy depending on the stage. Recurrence is managed based on prior treatment and extent of disease. The goal is elimination of cervical cancer as a public health problem by 2030.
Cervical canser screening.ppt
Cervical cancer screening involves testing asymptomatic women for pre-cancerous lesions to prevent cancer from developing. An effective screening test must detect a prevalent disease with mortality/morbidity at a preclinical stage. Cervical pre-cancer is caused by HPV and progresses from CIN1 to CIN3 over years before cancer. Screening methods include Pap smear, HPV testing, and VIA. Women who are sexually active should be screened starting at age 21. Abnormal results may indicate CIN1-3 and are treated with local destructive therapies like LLEP or cryotherapy to remove pre-cancerous cells. Treated women still require ongoing screening.
Breast cancer screening-2021 chan hio tong
This document discusses breast cancer screening and provides guidance on screening strategies based on risk level. It covers:
1) Screening modalities like mammography, ultrasound, MRI and their limitations. Mammography is the primary screening tool for average risk women aged 50-74.
2) Risk assessment factors like family history, genetic mutations, breast density, reproductive history which determine screening frequency and additional tests. Women at high risk start screening earlier and more frequently.
3) Two case studies where mammography limitations are demonstrated. Early detection through clinical exams and additional tests led to cancer diagnosis in both cases. Regular screening tailored to risk level can improve early detection.
Mon 8-00 Prostate Cancer Screening in the Post-USPSTF Era_0.pptx
This document discusses prostate cancer screening and recommendations. It begins with a case presentation of a 54-year-old man before discussing the US Preventive Services Task Force recommendations against PSA screening. It then reviews the goals of cancer screening, basics of PSA testing and prostate cancer, impact of the Task Force, and ways to improve screening through risk stratification using newer biomarkers, imaging, and genetic profiling to avoid overdiagnosis while identifying high-risk cancers.
Ovarian Cancer Research and Prevention, Andrew Berchuck, MD
The document discusses recent research on early detection of ovarian cancer, including findings from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Key points include:
- UKCTOCS found that multimodal screening (MMS) using CA125 and ultrasound was more sensitive (86%) than ultrasound alone (63%) for detecting early stage ovarian cancers, and led to fewer unnecessary surgeries.
- Mortality was reduced by 15-28% with MMS compared to no screening over 7-14 years of follow up. MMS also resulted in more cancers being diagnosed at early stages.
- Further analysis of UKCTOCS data is needed to better establish the benefits and
Similar to Nicolas Mottet: How to organize PSA screening (20)
Evolving recommendations in prostate cancer screening
Evolving recommendations in prostate cancer screening
Prostate cancer modernising the diagnostic pathway 2013-06-11 by Marc Laniado
Prostate cancer modernising the diagnostic pathway 2013-06-11 by Marc Laniado
BALKAN MCO 2011 - A. Anttila - The European Commission programme for cervical...
BALKAN MCO 2011 - A. Anttila - The European Commission programme for cervical...
Cervical Cancer Screening - HPV - www.jinekolojivegebelik.com
Cervical Cancer Screening - HPV - www.jinekolojivegebelik.com
Super early cancer screening for the ultra rich Asian
Super early cancer screening for the ultra rich Asian
Mon 8-00 Prostate Cancer Screening in the Post-USPSTF Era_0.pptx
Mon 8-00 Prostate Cancer Screening in the Post-USPSTF Era_0.pptx
Ovarian Cancer Research and Prevention, Andrew Berchuck, MD
Ovarian Cancer Research and Prevention, Andrew Berchuck, MD
Recently uploaded
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
cosmetics and cosmeceuticals
Muskan
mpharm
2nd semester
Guru Gobind Singh college of pharmacy, yamunanagar, haryana
Know the difference between Endodontics and Orthodontics.
Your smile is beautiful.
Let’s be honest. Maintaining that beautiful smile is not an easy task. It is more than brushing and flossing. Sometimes, you might encounter dental issues that need special dental care. These issues can range anywhere from misalignment of the jaw to pain in the root of teeth.
Giloy in Ayurveda - Classical Categorization and Synonyms
Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
une 2024 Oncology Cartoons By Dr Kanhu Charan Patro
biomechanics of running. Dr.dhwani.pptx
The biomechanics of running involves the study of the mechanical principles underlying running movements. It includes the analysis of the running gait cycle, which consists of the stance phase (foot contact to push-off) and the swing phase (foot lift-off to next contact). Key aspects include kinematics (joint angles and movements, stride length and frequency) and kinetics (forces involved in running, including ground reaction and muscle forces). Understanding these factors helps in improving running performance, optimizing technique, and preventing injuries.
Top Travel Vaccinations in Manchester
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...Université de Montréal
“Psychiatry and the Humanities”: An Innovative Course at the University of Montreal Expanding the medical model to embrace the humanities. Link: https://www.psychiatrictimes.com/view/-psychiatry-and-the-humanities-an-innovative-course-at-the-university-of-montrealTravel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
Acute Gout Care & Urate Lowering Therapy .pdf
In this document , the management of acute gout attacks and a description of urate lowering therapy is mentioned.
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Fallopian tube blockage may cause female infertility. For treatment, herbal medicine Fuyan Pill can be a solution.
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
Time-lapse embryo monitoring is an advanced imaging technique used in IVF to continuously observe embryo development. It captures high-resolution images at regular intervals, allowing embryologists to select the most viable embryos for transfer based on detailed growth patterns. This technology enhances embryo selection, potentially increasing pregnancy success rates.
PGx Analysis in VarSeq: A User’s Perspective
Since our release of the PGx capabilities in VarSeq, we’ve had a few months to gather some insights from various use cases. Some users approach PGx workflows by means of array genotyping or what seems to be a growing trend of adding the star allele calling to the existing NGS pipeline for whole genome data. Luckily, both approaches are supported with the VarSeq software platform. The genotyping method being used will also dictate what the scope of the tertiary analysis will be. For example, are your PGx reports a standalone pipeline or would your lab’s goal be to handle a dual-purpose workflow and report on PGx + Diagnostic findings.
The purpose of this webcast is to:
Discuss and demonstrate the approaches with array and NGS genotyping methods for star allele calling to prep for downstream analysis.
Following genotyping, explore alternative tertiary workflow concepts in VarSeq to handle PGx reporting.
Moreover, we will include insights users will need to consider when validating their PGx workflow for all possible star alleles and options you have for automating your PGx analysis for large number of samples. Please join us for a session dedicated to the application of star allele genotyping and subsequent PGx workflows in our VarSeq software.
What is Obesity? How to overcome Obesity?
Obesity is a chronic complex disease defined by excessive fat deposits that can impair health.
Recently uploaded (20)
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
Know the difference between Endodontics and Orthodontics.
Know the difference between Endodontics and Orthodontics.
Giloy in Ayurveda - Classical Categorization and Synonyms
Giloy in Ayurveda - Classical Categorization and Synonyms
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
Nicolas Mottet: How to organize PSA screening
- 1. How to organize / re-introduce PSA screening N. Mottet Urology department St Etienne Chairman EAU-ESTRO-ESUR-SIOG prostate cancer guidelines
- 2. Disclosure None with the topic
- 4. SCREENING ? Unchanged in 2019
- 5. AT RISK ? Genetic testing (such as BRCA) considered too preliminary to be included Population at risk Unchanged in 2019
- 6. EARLY PSA IN GUIDELINES Very early PSA suggested Early PSA (40-45 yrs of age) predicts PCa mortality / advanced disease at diagnosis Vickers BMJ 2013, Carlsson BMJ 2014, Preston J Clin Oncol 2016 THEN decreases follow up pressure if not at risk Unchanged in 2019
- 7. AT RISK: WHAT TO DO ? Once at risk, what to do ? 2019 table
- 8. OFFERED TOOLS Risk calculator Pereira-Azevedo Transl Androl Urol 2018 For free 30 – 40% biopsy less
- 9. OFFERED TOOLS Biological tests Van Oort. Prost Cancer Prost Dis 2017 Constant limitations Most studies: retrospective No clear definition of high risk disease (outside Gleason often > 7) Intrinsic test validity almost never done Cost effectiveness still questionable for many
- 10. Mp MRI: THE NEW TOOL mpMRI 2019 table Mp-MRI quality control: a must have
- 11. HOW OFTEN ? Intervals for early detection Individualized based on risk Unchanged in 2019
- 12. WHEN TO STOP ? When to stop ? Therefore no definitive age limit [Droz Eur Urol 2017] But comorbidities: the main discriminating factor Charlson comorbidity index: validated tool in PCa Unchanged in 2019
- 13. LOW RISK FINDING Dealing with overtreatment Intermediate risk Unchanged in 2019
- 14. TO CONCLUDE Finally Early diagnosis: only way to find "early" aggressive lesions Awareness of men Individualization and and counseling mandatory Cutting the link between diagnosis / treatment Clarifying clinically significant PCa to be improved